Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av tolerabilitet, sikkerhet og effektivitet av Asciminib hos pasienter med Philadelphia-kromosompositiv kronisk myeloid leukemi i kronisk fase i Tyskland (ASC2ADHERE)

5. november 2026 oppdatert av: Novartis Pharmaceuticals

En ikke-intervensjonell studie om toleransen, sikkerheten og effekten av Asciminib hos nydiagnostiserte og tidligere behandlede pasienter med Philadelphia-kromosompositiv kronisk myeloisk leukemi i kronisk fase i Tyskland - ASC2ADHERE-studien

The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).

Studieoversikt

Status

Rekruttering

Studietype

Observasjonsmessig

Registrering (Antatt)

380

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Novartis Pharmaceuticals

Studiesteder

      • Amberg, Tyskland, 92224
        • Rekruttering
        • Novartis Investigative Site
      • Bad Friedrichshall, Tyskland, 74177
        • Rekruttering
        • Novartis Investigative Site
      • Bad Liebenwerda, Tyskland, 04924
        • Rekruttering
        • Novartis Investigative Site
      • Bad Saarow, Tyskland, 15526
        • Rekruttering
        • Novartis Investigative Site
      • Berlin, Tyskland, 10437
        • Rekruttering
        • Novartis Investigative Site
      • Berlin, Tyskland, 10365
        • Rekruttering
        • Novartis Investigative Site
      • Berlin, Tyskland, 12552
        • Rekruttering
        • Novartis Investigative Site
      • Berlin, Tyskland, 10559
        • Rekruttering
        • Novartis Investigative Site
      • Berlin, Tyskland, 12487
        • Rekruttering
        • Novartis Investigative Site
      • Bremerhaven, Tyskland, 27568
        • Rekruttering
        • Novartis Investigative Site
      • Buchholz Nordheide, Tyskland, 21244
        • Rekruttering
        • Novartis Investigative Site
      • Cottbus, Tyskland, 03046
        • Rekruttering
        • Novartis Investigative Site
      • Deggendorf, Tyskland, 94469
        • Rekruttering
        • Novartis Investigative Site
      • Detmold, Tyskland, 32756
        • Rekruttering
        • Novartis Investigative Site
      • Dorfen, Tyskland, 84405
        • Rekruttering
        • Novartis Investigative Site
      • Dortmund, Tyskland, 44263
        • Rekruttering
        • Novartis Investigative Site
      • Dresden, Tyskland, 01307
        • Rekruttering
        • Novartis Investigative Site
      • Dresden, Tyskland, 01127
        • Rekruttering
        • Novartis Investigative Site
      • Düren, Tyskland, 52353
        • Rekruttering
        • Novartis Investigative Site
      • Erfurt, Tyskland, 99085
        • Rekruttering
        • Novartis Investigative Site
      • Erfurt, Tyskland, 99084
        • Rekruttering
        • Novartis Investigative Site
      • Eschweiler, Tyskland, 52249
        • Rekruttering
        • Novartis Investigative Site
      • Göttingen, Tyskland, 37073
        • Rekruttering
        • Novartis Investigative Site
      • Hanover, Tyskland, 30161
        • Rekruttering
        • Novartis Investigative Site
      • Hanover, Tyskland, 30625
        • Rekruttering
        • Novartis Investigative Site
      • Hildesheim, Tyskland, 31135
        • Rekruttering
        • Novartis Investigative Site
      • Kiel, Tyskland, 24105
        • Rekruttering
        • Novartis Investigative Site
      • Leipzig, Tyskland, 04103
        • Rekruttering
        • Novartis Investigative Site
      • Leverkusen, Tyskland, 51375
        • Rekruttering
        • Novartis Investigative Site
      • Mutlangen, Tyskland, 73557
        • Rekruttering
        • Novartis Investigative Site
      • Naunhof, Tyskland, 04683
        • Rekruttering
        • Novartis Investigative Site
      • Neuss, Tyskland, 41462
        • Rekruttering
        • Novartis Investigative Site
      • Offenburg, Tyskland, 77654
        • Rekruttering
        • Novartis Investigative Site
      • Oldenburg, Tyskland, 26121
        • Rekruttering
        • Novartis Investigative Site
      • Parchim, Tyskland, 19370
        • Rekruttering
        • Novartis Investigative Site
      • Potsdam, Tyskland, 14467
        • Rekruttering
        • Novartis Investigative Site
      • Potsdam, Tyskland, 14482
        • Rekruttering
        • Novartis Investigative Site
      • Schorndorf, Tyskland, 73614
        • Rekruttering
        • Novartis Investigative Site
      • Schwetzingen, Tyskland, 68723
        • Rekruttering
        • Novartis Investigative Site
      • Soest, Tyskland, 59494
        • Rekruttering
        • Novartis Investigative Site
      • Stade, Tyskland, 21680
        • Rekruttering
        • Novartis Investigative Site
      • Torgau, Tyskland, 04860
        • Rekruttering
        • Novartis Investigative Site
      • Ulm, Tyskland, 89081
        • Rekruttering
        • Novartis Investigative Site
      • Wetzlar, Tyskland, 35578
        • Rekruttering
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Baden-Baden, Baden-Wurttemberg, Tyskland, 76532
        • Rekruttering
        • Novartis Investigative Site
      • Heidenheim, Baden-Wurttemberg, Tyskland, 89522
        • Rekruttering
        • Novartis Investigative Site
      • Schwäbisch Hall, Baden-Wurttemberg, Tyskland, 74523
        • Rekruttering
        • Novartis Investigative Site
      • Winnenden, Baden-Wurttemberg, Tyskland, 71364
        • Rekruttering
        • Novartis Investigative Site
    • Bavaria
      • Aschaffenburg, Bavaria, Tyskland, 63739
        • Rekruttering
        • Novartis Investigative Site
      • Augsburg, Bavaria, Tyskland, 86152
        • Rekruttering
        • Novartis Investigative Site
      • Donauwörth, Bavaria, Tyskland, 86609
        • Rekruttering
        • Novartis Investigative Site
      • Herrsching am Ammersee, Bavaria, Tyskland, 82211
        • Rekruttering
        • Novartis Investigative Site
      • Kempten (Allgäu), Bavaria, Tyskland, 87439
        • Rekruttering
        • Novartis Investigative Site
      • Landsberg am Lech, Bavaria, Tyskland, 86899
        • Rekruttering
        • Novartis Investigative Site
      • Munich, Bavaria, Tyskland, 81241
        • Rekruttering
        • Novartis Investigative Site
      • Munich, Bavaria, Tyskland, 81377
        • Rekruttering
        • Novartis Investigative Site
      • Regensburg, Bavaria, Tyskland, 93053
        • Rekruttering
        • Novartis Investigative Site
    • Free Hanseatic City of Bremen
      • Bremerhaven, Free Hanseatic City of Bremen, Tyskland, 27576
        • Rekruttering
        • Novartis Investigative Site
    • Hesse
      • Kassel, Hesse, Tyskland, 34125
        • Rekruttering
        • Novartis Investigative Site
      • Offenbach, Hesse, Tyskland, 63065
        • Rekruttering
        • Novartis Investigative Site
    • Lower Saxony
      • Goslar, Lower Saxony, Tyskland, 38642
        • Rekruttering
        • Novartis Investigative Site
      • Rotenburg (Wümme), Lower Saxony, Tyskland, 27356
        • Rekruttering
        • Novartis Investigative Site
      • Twistringen, Lower Saxony, Tyskland, 27239
        • Rekruttering
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Tyskland, 50674
        • Rekruttering
        • Novartis Investigative Site
      • Cologne, North Rhine-Westphalia, Tyskland, 50677
        • Rekruttering
        • Novartis Investigative Site
      • Cologne, North Rhine-Westphalia, Tyskland, 51103
        • Rekruttering
        • Novartis Investigative Site
      • Solingen, North Rhine-Westphalia, Tyskland, 42653
        • Rekruttering
        • Novartis Investigative Site
      • Wesel, North Rhine-Westphalia, Tyskland, 46483
        • Rekruttering
        • Novartis Investigative Site
    • Saxony
      • Zittau, Saxony, Tyskland, 02763
        • Rekruttering
        • Novartis Investigative Site
    • Saxony-Anhalt
      • Halle, Saxony-Anhalt, Tyskland, 06110
        • Rekruttering
        • Novartis Investigative Site
      • Merseburg, Saxony-Anhalt, Tyskland, 06217
        • Rekruttering
        • Novartis Investigative Site
    • Schleswig-Holstein
      • Oldenburg in Holstein, Schleswig-Holstein, Tyskland, 23758
        • Rekruttering
        • Novartis Investigative Site
    • Thuringia
      • Altenburg, Thuringia, Tyskland, 04600
        • Rekruttering
        • Novartis Investigative Site
      • Saalfeld, Thuringia, Tyskland, 07318
        • Rekruttering
        • Novartis Investigative Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 100 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Adult Ph+ CML-CP patients, either newly diagnosed or previously treated with one ATP-competitive TKI, who initiate TKI treatment as recommended by the treating physician in a hematology center in Germany.

Beskrivelse

Inclusion criteria:

  1. Written informed consent must be obtained before participation in the study/prior to any study-related documentation.
  2. Adult patients (≥18 years of age) with a confirmed diagnosis of Ph+ CML-CP. The presence of the Philadelphia chromosome may alternatively be confirmed by molecular detection of a BCR::ABL1 fusion gene/transcript (e.g., by reverse transcription polymerase chain reaction (RT-PCR)), in accordance with the World Health Organization (WHO) 2022 classification.
  3. Patients who are either newly diagnosed or have received treatment with exactly one prior TKI. Prior TKI treatment is only permitted for patients in the Asciminib Cohort. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be newly diagnosed and must not have received any prior TKI treatment.
  4. Patients for whom the treating physician has made a clinical decision to initiate treatment with asciminib or another TKI (imatinib, dasatinib, bosutinib, nilotinib) as part of routine care. The clinical decision for treatment must have been made prior to enrollment. Treatment must not have started more than 14 days before study inclusion, and treatment may also begin after baseline assessment.
  5. Patients willing to participate in routine follow-up visits and complete patient-reported outcome questionnaires over the course of the study.

Exclusion criteria:

  1. Patients with contraindications to their respective chronic myeloid leukemia (CML) treatment as per the applicable Summary of Product Characteristics (SmPC) and relevant national treatment guidelines (e.g. Onkopedia CML), as well as additional disease- or treatment-related characteristics associated with distinct clinical scenarios that differ from the intended study population, including situations with specific treatment requirements or limited comparability, in which reliable interpretation of study outcomes may not be feasible, including the following asciminib specific considerations:

    • In first- or second-line treatment: presence of BCR::ABL1 fusion transcripts lacking exon a2 (e.g. e13a3, e14a3, e1a3).

    • In second-line treatment:

      • known BCR::ABL1 mutations associated with partial or complete resistance to asciminib (e.g. M244V, F359I/V/C).
      • presence of the BCR::ABL1 T315I mutation, regardless of eligibility for treatment according to SmPC (e.g., specific indication and dosing regimens).
  2. Patients receiving or planned to receive asciminib or other TKIs outside the approved label (off-label use), including use in unapproved dosing regimens or frequency not covered by the respective SmPC.

  3. Patients currently participating in an interventional clinical trial.

  4. Patients unable or unwilling to provide written informed consent.

  5. Patients who are unable to reliably complete patient-reported outcome questionnaires due to cognitive or language limitations relevant to the study assessments.

  6. Patients for whom long-term follow-up is not feasible due to expected relocation or other logistical constraints.

  7. The restriction to a maximum of one prior ATP-competitive TKI applies exclusively to patients treated with asciminib. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be TKI-naïve and are included at the start of their first-line TKI therapy and are not eligible if they have received any prior TKI treatment.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Asciminib Cohort

Adult patients with Ph+ CML-CP, either newly diagnosed or previously treated with one TKI, who are treated with asciminib.

Imatinib Cohort

Adult patients newly diagnosed with Ph+ CML-CP treated with imatinib who have not received any prior TKI treatment.

Second-generation TKI Cohort

Adult patients newly diagnosed with Ph+ CML-CP treated with dasatinib, bosutinib, or nilotinib who have not received any prior TKI treatment.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Patients With Major Molecular Response (MMR) at 12 Months
Tidsramme: Month 12

MMR is defined as a BCR::ABL1 level ≤ 0.1% according to the International Scale (IS).

Month 12

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Andel pasienter etter årsak til TKI-behandlingsbeslutning dokumentert av behandlende lege
Tidsramme: Baseline
Baseline
Andel pasienter med dosereduksjon etter årsak til dosereduksjon
Tidsramme: 3, 6, 9, 12, 18, 21 og 24 måneder
3, 6, 9, 12, 18, 21 og 24 måneder
Andel pasienter med avbrutt behandling etter årsak til avbrudd
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
3, 6, 9, 12, 15, 18, 21 og 24 måneder
Andel av pasienter som avbrøt behandlingen, årsak til avbrudd
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
3, 6, 9, 12, 15, 18, 21 og 24 måneder
Tid til behandlingsavbrudd
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
3, 6, 9, 12, 15, 18, 21 og 24 måneder
Tid til behandlingsavbrudd
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
3, 6, 9, 12, 15, 18, 21 og 24 måneder
Tid til dosereduksjon
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
3, 6, 9, 12, 15, 18, 21 og 24 måneder
Tid til avsluttet behandling på grunn av uønskede hendelser (TTDAE)
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
3, 6, 9, 12, 15, 18, 21 og 24 måneder
Percentage of Patients by Clinical Characteristic
Tidsramme: Baseline

Characteristics include, but are not limited to, detection of Philadelphia chromosome or BCR::ABL1 transcript, prior treatment, and Eastern Cooperative Oncology Group (ECOG) performance status.

Baseline
Percentage of Patients With Early Molecular Response (EMR) at 3 Months
Tidsramme: Month 3

EMR is defined as BCR::ABL1 ≤10% IS.

Month 3
Percentage of Patients With Molecular Response 2 (MR2)
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months

MR2 is defined as BCR::ABL1 ≤1% IS.

3, 6, 9, 12, 15, 18, 21, and 24 months
Percentage of Patients With MMR
Tidsramme: 3, 6, 9, 15, 18, 21, and 24 months

MMR is defined as BCR::ABL1 ≤0.1% IS.

3, 6, 9, 15, 18, 21, and 24 months
Percentage of Patients With Deep Molecular Response: MR4.0
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months

Deep Molecular Response (MR4.0): ≤0.01% BCR::ABL1 IS and Reference gene copies >10,000 ABL1 or >24,000 GUSB.

3, 6, 9, 12, 15, 18, 21, and 24 months
Percentage of Patients With Deep Molecular Response: MR4.5
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months

Deep Molecular Response (MR4.5): ≤0.0032% BCR::ABL1 IS and Reference gene copies >32,000 ABL1 or >77,000 GUSB.

3, 6, 9, 12, 15, 18, 21, and 24 months
Percentage of Patients With Deep Molecular Response: MR5
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months

Deep Molecular Response (MR5): ≤0.001% BCR::ABL1 IS and Reference gene copies >100,000 ABL1 or >240,000 GUSB.

3, 6, 9, 12, 15, 18, 21, and 24 months
Medication Adherence Report Scale (MARS-5) Score
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months

The MARS-5 questionnaire is a validated self-report questionnaire developed to assess patient adherence to prescribed medication, focusing on both intentional and unintentional non-adherence. It consists of 5 items, each rated on a 5-point Likert Scale from 0 (always) to 5 (never). The total score ranges from 5 to 25, with higher scores indicating better adherence to treatment.

3, 6, 9, 12, 15, 18, 21, and 24 months
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months

The EORTC QLQ-C30 contains 30 questions answered by the patient. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but 2 questions have 4-point scales ranging from "Not at all" to "Very much." The 2 questions concerning global health status/QOL have 7-point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement.

3, 6, 9, 12, 15, 18, 21, and 24 months
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for CML (EORTC QLQ-CML24) Score
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months

The EORTC QLQ-CML24 was designed to supplement the QLQ-C30 - the QLQ-CML24 is not a stand-alone instrument but is to be used in conjunction with the QLQ-C30.

The EORTC QLQ-CML24 is composed of 4 multi-item scales and 2 single-item scales. The module consists of 24 items assessing symptom burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items are measured on 4 levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores are averaged and transformed to 0 to 100.

A higher score in symptom burden, impact on worry/mood, impact on daily life, and body image problems domains indicates a worse outcome. A higher score in satisfaction with social life and satisfaction with care and information domains indicates a higher level of satisfaction.

3, 6, 9, 12, 15, 18, 21, and 24 months
Work Productivity and Activity Impairment - General Health (WPAI-GH) Score
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months

The WPAI-GH is a patient-reported 6 item questionnaire which addresses absenteeism, presenteeism, overall work productivity loss, and activity impairment for the 7 days prior to the assessment. Work productivity and activity impairment outcomes are presented as impairment percentages ranging from 0 to 100 with a higher percentage indicating greater impairment and less productivity.

3, 6, 9, 12, 15, 18, 21, and 24 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. april 2026

Primær fullføring (Antatt)

30. september 2030

Studiet fullført (Antatt)

30. september 2030

Datoer for studieregistrering

Først innsendt

16. april 2026

Først innsendt som oppfylte QC-kriteriene

16. april 2026

Først lagt ut (Faktiske)

24. april 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere